OOIR: Observatory of International Research

Papers

(The H4-Index of Haematologica is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors	108
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia	106
Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia	99
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma	82
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE t	77
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	74
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide	69
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition	67
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma	64
Leukemic stem cells and therapy resistance in acute myeloid leukemia	62
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia	58
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT	58
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients	56
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma	51
Targeting the tumor microenvironment in chronic lymphocytic leukemia	50
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis	50
VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome)	49
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies	49
Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS	49
Post-mortem findings in vaccine-induced thrombotic thombocytopenia	48
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies	48
MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma	46
Red cell transfusion and alloimmunization in sickle cell disease	46
The interactome of the N-terminus of band 3 regulates red blood cell metabolism and storage quality	46
The clinical impact of the molecular landscape of acute myeloid leukemia	45

Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021?	44
A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol	43
Complement dysregulation is associated with severe COVID-19 illness	40
Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood s	39
Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy	39
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome	39
Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis	38
Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York	36
Unique ethnic features of <I>DDX41</I> mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia	36
Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter	36
Maintenance therapy for <i>FLT3-ITD</i>-mutated acute myeloid leukemia	36
Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines	36
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma	36